Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448229 | 1.00 | KMT2A (0.58) | KMT2AOPRK1SIGMAR1OPRD1ALDH1A1 | |
| SCHEMBL5452616 | 0.84 | L3MBTL1 (0.52) | KMT2AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5452613 | 0.84 | L3MBTL1 (0.52) | KMT2AALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL24095117 | 0.80 | KMT2A (0.73) | KMT2AOPRK1SIGMAR1OPRD1OPRM1 | |
| SCHEMBL7384253 | 0.79 | KMT2A (0.59) | KMT2AOPRK1SIGMAR1OPRD1CYP3A4 | |
| SCHEMBL13504125 | 0.79 | KMT2A (0.68) | KMT2AOPRK1SIGMAR1OPRD1CYP3A4 | |
| SCHEMBL11687083 | 0.79 | KMT2A (0.68) | KMT2AOPRK1SIGMAR1OPRD1CYP3A4 | |
| SCHEMBL7384247 | 0.79 | KMT2A (0.59) | KMT2AOPRK1SIGMAR1OPRD1CYP3A4 | |
| SCHEMBL7050115 | 0.78 | TSHR (0.57) | ALDH1A1CYP2C19 | |
| SCHEMBL5449639 | 0.75 | HRH3 (0.54) | KMT2AOPRK1OPRD1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007137098-A2 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270434-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270434-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARD, PPARG, PPARA | KMT2A 3154/4885OPRK1 1827/4885SIGMAR1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.